Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study

• Main Authors: Luciano Ibba (Author), Sara Di Giulio (Author), Luigi Gargiulo (Author), Paola Facheris (Author), Chiara Perugini (Author), Antonio Costanzo (Author), Alessandra Narcisi (Author), Mario Valenti (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Psoriasis is a chronic skin disease driven by immune system dysfunction and associated with increased cardiovascular risk and metabolic disorders. Risankizumab is an anti-interleukin-23 humanized monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis.Object...